News
OGEN
1.500
-2.60%
-0.040
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 1d ago
Weekly Report: what happened at OGEN last week (0630-0704)?
Weekly Report · 1d ago
Oragenics Raises $16.5M Through Public Offering
TipRanks · 6d ago
Oragenics Completes Approximately $16.5 Million Offering
Barchart · 6d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 07/01 21:05
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 07/01 17:05
Nasdaq Dips 150 Points; US ISM Manufacturing PMI Rises In June
Benzinga · 07/01 16:51
Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
TipRanks · 07/01 16:42
US Stocks Mixed; Dow Gains Over 50 Points
Benzinga · 07/01 14:08
Why Is Oragenics Stock (OGEN) Down 55% Today?
TipRanks · 07/01 13:00
Oragenics trading resumes
TipRanks · 07/01 12:50
Oragenics announces $20M preferred stock offering; shares surge over 138%
Seeking Alpha · 07/01 12:46
Oragenics prices 800,000 shares of Preferred Stock at $25.00 in public offering
TipRanks · 07/01 12:41
Oragenics Prices Public Offering Of Up To $20M Of Preferred Stock And Warrants
Benzinga · 07/01 12:35
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 07/01 12:07
Oragenics trading halted, news pending
TipRanks · 07/01 12:05
Why Thumzup Media Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Benzinga · 07/01 09:23
Weekly Report: what happened at OGEN last week (0623-0627)?
Weekly Report · 06/30 09:34
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 06/27 21:05
Weekly Report: what happened at OGEN last week (0616-0620)?
Weekly Report · 06/23 09:32
More
Webull provides a variety of real-time OGEN stock news. You can receive the latest news about Oragenics through multiple platforms. This information may help you make smarter investment decisions.
About OGEN
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It focuses on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product, ONP-002, is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its other product candidate, ONP-001, is in its early stage and clinical trials.